Citations (84)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (11)
Maka Siamashvili & Stephen N. Davis. (2021) Sodium–glucose cotransporter 2 inhibitors for the management of type 2 diabetes. Expert Opinion on Pharmacotherapy 22:16, pages 2181-2198.
Read now
Read now
Angelo Maria Patti, Rosaria Vincenza Giglio, Nikolaos Papanas, Manfredi Rizzo & Ali A. Rizvi. (2019) Future perspectives of the pharmacological management of diabetic dyslipidemia. Expert Review of Clinical Pharmacology 12:2, pages 129-143.
Read now
Read now
A. Avogaro, A. Giaccari, P. Fioretto, S. Genovese, F. Purrello, F. Giorgino & S. Del Prato. (2017) A consensus statement for the clinical use of the renal sodium-glucose co-transporter-2 inhibitor dapagliflozin in patients with type 2 diabetes mellitus. Expert Review of Clinical Pharmacology 10:7, pages 763-772.
Read now
Read now
Paola Fioretto & Angelo Avogaro. (2017) Dapagliflozin: potential beneficial effects in the prevention and treatment of renal and cardiovascular complications in patients with type 2 diabetes. Expert Opinion on Pharmacotherapy 18:5, pages 517-527.
Read now
Read now
Kelly F Bell, Arie Katz & John J Sheehan. (2016) Quality measure attainment with dapagliflozin plus metformin extended-release as initial combination therapy in patients with type 2 diabetes: a post hoc pooled analysis of two clinical studies. Risk Management and Healthcare Policy 9, pages 231-241.
Read now
Read now
Catherine M Kuecker & Eva M Vivian. (2016) Patient considerations in type 2 diabetes – role of combination dapagliflozin–metformin XR. Diabetes, Metabolic Syndrome and Obesity 9, pages 25-35.
Read now
Read now
Curt J. Carlson & Marile L. Santamarina. (2016) Update review of the safety of sodium-glucose cotransporter 2 inhibitors for the treatment of patients with type 2 diabetes mellitus. Expert Opinion on Drug Safety 15:10, pages 1401-1412.
Read now
Read now
Helmut O. Steinberg. (2016) Sodium-glucose cotransporter 2 inhibitors and cardiovascular outcomes. Postgraduate Medicine 128:4, pages 398-408.
Read now
Read now
André J. Scheen. (2015) SGLT2 inhibition: efficacy and safety in type 2 diabetes treatment. Expert Opinion on Drug Safety 14:12, pages 1879-1904.
Read now
Read now
Michael A Nauck. (2014) Update on developments with SGLT2 inhibitors in the management of type 2 diabetes. Drug Design, Development and Therapy 8, pages 1380-1380.
Read now
Read now
Rosemarie Lajara. (2014) The potential role of sodium glucose co-transporter 2 inhibitors in combination therapy for type 2 diabetes mellitus. Expert Opinion on Pharmacotherapy 15:17, pages 2565-2585.
Read now
Read now
Articles from other publishers (73)
Tatsuhiko Urakami, Kei Yoshida & Junichi Suzuki. (2023) Efficacy of Low-dose Dapagliflozin in Young People with Type 1 Diabetes. Internal Medicine 62:2, pages 177-186.
Crossref
Crossref
越 孔. (2023) Effects of Daggligin on Metabolism in Elderly Patients with Type 2 Diabetes and Heart Failure. Advances in Clinical Medicine 13:04, pages 5520-5526.
Crossref
Crossref
鸿 王. (2023) Research Progress of Dapagliflozin in Treatment of Acute Myocardial Infarction Complicated with Type 2 Diabetes Mellitus. Advances in Clinical Medicine 13:02, pages 1667-1672.
Crossref
Crossref
Ahasanul Hasan, Farzana Zerin, Sreelakshmi N. Menon, Md. Ashraful Alam & Raquibul Hasan. (2022) Mechanism of canagliflozin-induced vasodilation in resistance mesenteric arteries and the regulation of systemic blood pressure. Journal of Pharmacological Sciences 150:4, pages 211-222.
Crossref
Crossref
Nataliia Kushnarova, Olesia Zinych, Alla Kovalchuk, Olha Prybyla & Kateryna Shyshkan-Shyshova. (2022) MECHANISMS OF THE INFLUENCE OF SODIUM-GLUCOSE COTRANSPORTER-2 INHIBITORS ON LDL RECEPTOR FUNCTION AND CARDIOVASCULAR RISK IN TYPE 2 DM (literature review). World Science:5(77).
Crossref
Crossref
Zhenya Wang, Mao Ye, Xiao-Jing Zhang, Peng Zhang, Jingjing Cai, Hongliang Li & Zhi-Gang She. (2022) Impact of NAFLD and its pharmacotherapy on lipid profile and CVD. Atherosclerosis 355, pages 30-44.
Crossref
Crossref
Ahasanul Hasan, Sreelakshmi N. Menon, Farzana Zerin & Raquibul Hasan. (2022) Dapagliflozin induces vasodilation in resistance-size mesenteric arteries by stimulating smooth muscle cell KV7 ion channels. Heliyon 8:5, pages e09503.
Crossref
Crossref
Petra Grubić Rotkvić, Zrinka Planinić, Ana-Marija Liberati Pršo, Jozica Šikić, Edvard Galić & Luka Rotkvić. (2021) The Mystery of Diabetic Cardiomyopathy: From Early Concepts and Underlying Mechanisms to Novel Therapeutic Possibilities. International Journal of Molecular Sciences 22:11, pages 5973.
Crossref
Crossref
Eva Kralova, Margareta Marusakova, Katarina Hadova, Peter Krenek & Jan Klimas. (2021) Dapagliflozin elevates plasma high-density lipoprotein levels and influences visceral fat gene expression in streptozotocin-induced diabetes mellitus. Journal of Pharmacy and Pharmacology 73:6, pages 778-784.
Crossref
Crossref
Zsolt Szekeres, Kalman Toth & Eszter Szabados. (2021) The Effects of SGLT2 Inhibitors on Lipid Metabolism. Metabolites 11:2, pages 87.
Crossref
Crossref
Aml Mohamed Nada & Mariam Adel Younan. (2021) Dapagliflozin improves cardiovascular risk factors in Emirati patients with T2DM. Therapeutic Advances in Endocrinology and Metabolism 12, pages 204201882199536.
Crossref
Crossref
Connie B Newman, Michael J Blaha, Jeffrey B Boord, Bertrand Cariou, Alan Chait, Henry G Fein, Henry N Ginsberg, Ira J Goldberg, M Hassan Murad, Savitha Subramanian & Lisa R Tannock. (2020) Lipid Management in Patients with Endocrine Disorders: An Endocrine Society Clinical Practice Guideline. The Journal of Clinical Endocrinology & Metabolism 105:12, pages 3613-3682.
Crossref
Crossref
Petra Grubić Rotkvić, Maja Cigrovski Berković, Nikola Bulj & Luka Rotkvić. (2019) Minireview: are SGLT2 inhibitors heart savers in diabetes?. Heart Failure Reviews 25:6, pages 899-905.
Crossref
Crossref
Petra Grubić Rotkvić, Maja Cigrovski Berković, Nikola Bulj, Luka Rotkvić & Ivana Ćelap. (2020) Sodium-glucose cotransporter 2 inhibitors’ mechanisms of action in heart failure. World Journal of Diabetes 11:7, pages 269-279.
Crossref
Crossref
Angelo Maria Patti, Ali A Rizvi, Rosaria Vincenza Giglio, Anca Pantea Stoian, Daniela Ligi & Ferdinando Mannello. (2020) Impact of Glucose-Lowering Medications on Cardiovascular and Metabolic Risk in Type 2 Diabetes. Journal of Clinical Medicine 9:4, pages 912.
Crossref
Crossref
Ahmad Yehya & Archana Sadhu. (2020) Sodium–Glucose Cotransporter 2 Inhibitor–Associated Prolonged Euglycemic Diabetic Ketoacidosis in Type 2 Diabetes: A Case Report and Literature Review. Clinical Diabetes 38:1, pages 112-116.
Crossref
Crossref
Mauro Rigato, Gian Paolo Fadini & Angelo Avogaro. 2020. Diabetes Complications, Comorbidities and Related Disorders. Diabetes Complications, Comorbidities and Related Disorders
131
159
.
Damilola D. Adingupu, Sven O. Göpel, Julia Grönros, Margareta Behrendt, Matus Sotak, Tasso Miliotis, Ulrika Dahlqvist, Li-Ming Gan & Ann-Cathrine Jönsson-Rylander. (2019) SGLT2 inhibition with empagliflozin improves coronary microvascular function and cardiac contractility in prediabetic ob/ob−/− mice. Cardiovascular Diabetology 18:1.
Crossref
Crossref
Takaaki Sakai & Shinichiro Miura. (2019) Effects of Sodium-Glucose Cotransporter 2 Inhibitor on Vascular Endothelial and Diastolic Function in Heart Failure With Preserved Ejection Fraction ― Novel Prospective Cohort Study ―. Circulation Reports 1:7, pages 286-295.
Crossref
Crossref
Satoru Kuriyama. (2018) Protection of the kidney with sodium–glucose cotransporter 2 inhibitors: potential mechanisms raised by the large-scaled randomized control trials. Clinical and Experimental Nephrology 23:3, pages 304-312.
Crossref
Crossref
Sang Hyun ParkYoung Ju ChoiEun-Jung Rhee & Kab Bum Huh. (2019) Retrospective Analysis of the Efficacy of Dapagliflozin in Patients with Type 2 Diabetes in a Primary Clinic in Korea. Endocrinology and Metabolism 34:1, pages 70.
Crossref
Crossref
Sang Mok Yeo, Hayeon Park, Jin Hyuk Paek, Woo Yeong Park, Seungyeup Han, Sung Bae Park & Kyubok Jin. (2019) Ketoacidosis with euglycemia in a patient with type 2 diabetes mellitus taking dapagliflozin. Medicine 98:3, pages e14150.
Crossref
Crossref
Savitha Subramanian & Alan Chait. 2019. Encyclopedia of Endocrine Diseases. Encyclopedia of Endocrine Diseases
186
198
.
Mauro Rigato, Gian Paolo Fadini & Angelo Avogaro. 2019. Diabetes Complications, Comorbidities and Related Disorders. Diabetes Complications, Comorbidities and Related Disorders
1
29
.
Mauro Rigato, Gian Paolo Fadini & Angelo Avogaro. 2019. Diabetes Complications, Comorbidities and Related Disorders. Diabetes Complications, Comorbidities and Related Disorders
1
29
.
Paola Fioretto, Stefano Del Prato, John B. Buse, Ronald Goldenberg, Francesco Giorgino, Daniel Reyner, Anna Maria Langkilde, C. David Sjöström & Peter Sartipy. (2018) Efficacy and safety of dapagliflozin in patients with type 2 diabetes and moderate renal impairment (chronic kidney disease stage 3A): The DERIVE Study. Diabetes, Obesity and Metabolism 20:11, pages 2532-2540.
Crossref
Crossref
A.K. Pancholia. (2018) Sodium-glucose cotransporter-2 inhibition for the reduction of cardiovascular events in high-risk patients with diabetes mellitus. Indian Heart Journal 70:6, pages 915-921.
Crossref
Crossref
Debapriya BasuLesley-Ann HugginsDiego ScerboJoseph ObunikeAdam E. MullickPaul L. RothenbergNicholas A. Di ProsperoRobert H. EckelIra J. Goldberg. (2018) Mechanism of Increased LDL (Low-Density Lipoprotein) and Decreased Triglycerides With SGLT2 (Sodium-Glucose Cotransporter 2) Inhibition. Arteriosclerosis, Thrombosis, and Vascular Biology 38:9, pages 2207-2216.
Crossref
Crossref
Xiaoling Cai, Xueying Gao, Wenjia Yang, Yifei Chen, Simin Zhang, Lingli Zhou, Xueyao Han & Linong Ji. (2018) No disparity of the efficacy and all-cause mortality between Asian and non-Asian type 2 diabetes patients with sodium-glucose cotransporter 2 inhibitors treatment: A meta-analysis. Journal of Diabetes Investigation 9:4, pages 850-861.
Crossref
Crossref
Kalliopi Pafili, Manfredi Rizzo & Nikolaos Papanas. (2018) New antihyperglycaemic agents and cardiovascular disease. Current Opinion in Cardiology 33:4, pages 444-454.
Crossref
Crossref
Hongliang Li, Sung Eun Shin, Mi Seon Seo, Jin Ryeol An, Il-Whan Choi, Won-Kyo Jung, Amy L. Firth, Dae-Sung Lee, Mi-Jin Yim, Grace Choi, Jeong Min Lee, Sung Hun Na & Won Sun Park. (2018) The anti-diabetic drug dapagliflozin induces vasodilation via activation of PKG and Kv channels. Life Sciences 197, pages 46-55.
Crossref
Crossref
Christopher S. Wilcox, Wen Shen, David W. Boulton, Bruce R. Leslie & Steven C. Griffen. (2018) Interaction Between the Sodium‐Glucose–Linked Transporter 2 Inhibitor Dapagliflozin and the Loop Diuretic Bumetanide in Normal Human Subjects. Journal of the American Heart Association 7:4.
Crossref
Crossref
Mauro Rigato, Gian Paolo Fadini & Angelo Avogaro. 2018. Diabetes Complications, Comorbidities and Related Disorders. Diabetes Complications, Comorbidities and Related Disorders
131
159
.
Mauro Rigato, Gian Paolo Fadini & Angelo Avogaro. 2018. Diabetes. Epidemiology, Genetics, Pathogenesis, Diagnosis, Prevention, and Treatment. Diabetes. Epidemiology, Genetics, Pathogenesis, Diagnosis, Prevention, and Treatment
1
29
.
Hye Jin Lee, Min Jung Geum, Jae Song Kim, Soo Hyun Kim & Eun Sun Son. (2017) Dapagliflozin's Effects on Glycemia and Cardiovascular Risk Factors and Incidence of Adverse Events in Patients with Type 2 Diabetes. Korean Journal of Clinical Pharmacy 27:4, pages 214-220.
Crossref
Crossref
Seon-Ah Cha, Yong-Moon Park, Jae-Seung Yun, Tae-Seok Lim, Ki-Ho Song, Ki-Dong Yoo, Yu-Bae Ahn & Seung-Hyun Ko. (2017) A comparison of effects of DPP-4 inhibitor and SGLT2 inhibitor on lipid profile in patients with type 2 diabetes. Lipids in Health and Disease 16:1.
Crossref
Crossref
Toshiyuki Hayashi, Tomoyasu Fukui, Noriko Nakanishi, Saki Yamamoto, Masako Tomoyasu, Anna Osamura, Makoto Ohara, Takeshi Yamamoto, Yasuki Ito & Tsutomu Hirano. (2017) Dapagliflozin decreases small dense low-density lipoprotein-cholesterol and increases high-density lipoprotein 2-cholesterol in patients with type 2 diabetes: comparison with sitagliptin. Cardiovascular Diabetology 16:1.
Crossref
Crossref
Alan Chait & Ira Goldberg. (2017) Treatment of Dyslipidemia in Diabetes: Recent Advances and Remaining Questions. Current Diabetes Reports 17:11.
Crossref
Crossref
E Lioudaki, M Whyte, ES Androulakis, KG Stylianou, EK Daphnis & ES Ganotakis. (2017) Renal Effects of SGLT‐2 Inhibitors and Other Anti‐diabetic Drugs: Clinical Relevance and Potential Risks. Clinical Pharmacology & Therapeutics 102:3, pages 470-480.
Crossref
Crossref
Bart Staels. (2017) Cardiovascular Protection by Sodium Glucose Cotransporter 2 Inhibitors: Potential Mechanisms. The American Journal of Cardiology 120:1, pages S28-S36.
Crossref
Crossref
Maria Assunta Potenza, Carmela Nacci, Maria Antonietta De Salvia, Luca Sgarra, Massimo Collino & Monica Montagnani. (2017) Targeting endothelial metaflammation to counteract diabesity cardiovascular risk: Current and perspective therapeutic options. Pharmacological Research 120, pages 226-241.
Crossref
Crossref
Bart Staels. (2017) Cardiovascular Protection by Sodium Glucose Cotransporter 2 Inhibitors: Potential Mechanisms. The American Journal of Medicine 130:6, pages S30-S39.
Crossref
Crossref
Ashley M. Zurek, Raghunandan Yendapally & Elizabeth M. Urteaga. (2017) A Review of the Efficacy and Safety of Sodium–Glucose Cotransporter 2 Inhibitors: A Focus on Diabetic Ketoacidosis. Diabetes Spectrum 30:2, pages 137-142.
Crossref
Crossref
Matthew J. Budoff & John P. H. Wilding. (2017) Effects of canagliflozin on cardiovascular risk factors in patients with type 2 diabetes mellitus. International Journal of Clinical Practice 71:5, pages e12948.
Crossref
Crossref
Paresh Dandona & Ajay Chaudhuri. (2017) Sodium-glucose co-transporter 2 inhibitors for type 2 diabetes mellitus: An overview for the primary care physician. International Journal of Clinical Practice 71:5, pages e12937.
Crossref
Crossref
Andrew McGovern, Michael Feher, Neil Munro & Simon de Lusignan. (2017) Sodium-Glucose Co-Transporter-2 (SGLT2) Inhibitors: Comparing Trial and Real World Use (Study Protocol). Diabetes Therapy 8:2, pages 355-363.
Crossref
Crossref
Eirini Lioudaki, Emmanouil S. Androulakis, Martin Whyte, Konstantinos G. Stylianou, Eugenios K. Daphnis & Emmanouil S. Ganotakis. (2017) The Effect of Sodium-Glucose Co-transporter-2 (SGLT-2) Inhibitors on Cardiometabolic Profile; Beyond the Hypoglycaemic Action. Cardiovascular Drugs and Therapy 31:2, pages 215-225.
Crossref
Crossref
Jennifer M. Trujillo & Wesley A. Nuffer. (2017) Impact of Sodium-Glucose Cotransporter 2 Inhibitors on Nonglycemic Outcomes in Patients with Type 2 Diabetes. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 37:4, pages 481-491.
Crossref
Crossref
Matthew Hankins, Katherine Tsai, Joseph Kim & Niklas Hammar. (2017) Early drug use of dapagliflozin prescribed by general practitioners and diabetologists in Germany. Diabetes Research and Clinical Practice 125, pages 29-38.
Crossref
Crossref
Miles Fisher & Gerard McKayMiles Fisher. 2017. Essentials of SGLT2 Inhibitors in Diabetes. Essentials of SGLT2 Inhibitors in Diabetes
51
68
.
Nikolaus Marx & Darren K. McGuire. (2016) Sodium-glucose cotransporter-2 inhibition for the reduction of cardiovascular events in high-risk patients with diabetes mellitus. European Heart Journal 37:42, pages 3192-3200.
Crossref
Crossref
Anne E. de Leeuw & Rudolf A. de Boer. (2016) Sodium–glucose cotransporter 2 inhibition: cardioprotection by treating diabetes—a translational viewpoint explaining its potential salutary effects. European Heart Journal - Cardiovascular Pharmacotherapy 2:4, pages 244-255.
Crossref
Crossref
André J. Scheen. (2016) SGLT2 Inhibitors: Benefit/Risk Balance. Current Diabetes Reports 16:10.
Crossref
Crossref
Paola Fioretto, Traci A. Mansfield, Agata Ptaszynska, Yshai Yavin, Eva Johnsson & Shamik Parikh. (2016) Long-Term Safety of Dapagliflozin in Older Patients with Type 2 Diabetes Mellitus: A Pooled Analysis of Phase IIb/III Studies. Drugs & Aging 33:7, pages 511-522.
Crossref
Crossref
H. J. L. Heerspink, E. Johnsson, I. Gause-Nilsson, V. A. Cain & C. D. Sjöström. (2016) Dapagliflozin reduces albuminuria in patients with diabetes and hypertension receiving renin-angiotensin blockers. Diabetes, Obesity and Metabolism 18:6, pages 590-597.
Crossref
Crossref
Auryan Szalat, Ronen Durst & Eran Leitersdorf. (2016) Managing dyslipidaemia in type 2 diabetes mellitus. Best Practice & Research Clinical Endocrinology & Metabolism 30:3, pages 431-444.
Crossref
Crossref
Jonathan D. Schofield, Yifen Liu, Prasanna Rao-Balakrishna, Rayaz A. Malik & Handrean Soran. (2016) Diabetes Dyslipidemia. Diabetes Therapy 7:2, pages 203-219.
Crossref
Crossref
Tomoyuki Iwasaki & Masato Yoneda. (2015) Baseline low-density lipoprotein cholesterol predicts the hemoglobin A1c-lowering effect of dapagliflozin in Japanese patients with type 2 diabetes mellitus. Diabetology International 7:1, pages 77-82.
Crossref
Crossref
Heidi Storgaard, Jonatan I. Bagger, Filip K. Knop, Tina Vilsbøll & Jørgen Rungby. (2016) Diabetic Ketoacidosis in a Patient with Type 2 Diabetes After Initiation of Sodium-Glucose Cotransporter 2 Inhibitor Treatment. Basic & Clinical Pharmacology & Toxicology 118:2, pages 168-170.
Crossref
Crossref
Gema Ruiz-Hurtado & Luis M. Ruilope. (2015) Salutary cardiovascular effects of antidiabetic drugs. Journal of Hypertension 33:11, pages 2198-2199.
Crossref
Crossref
Thomas Forst & Christoph KaptizaRüdiger Göke & Burkhard Göke. 2015. Clinical Advances in Diabetes Mellitus. Clinical Advances in Diabetes Mellitus
50
57
.
S. A. Brunton. (2015) The potential role of sodium glucose co‐transporter 2 inhibitors in the early treatment of type 2 diabetes mellitus. International Journal of Clinical Practice 69:10, pages 1071-1087.
Crossref
Crossref
Ele Ferrannini & Ralph A. DeFronzo. (2015) Impact of glucose-lowering drugs on cardiovascular disease in type 2 diabetes. European Heart Journal 36:34, pages 2288-2296.
Crossref
Crossref
Giulia Ferrannini, Thomas Hach, Susanne Crowe, Arjun Sanghvi, Kevin D. Hall & Ele Ferrannini. (2015) Energy Balance After Sodium–Glucose Cotransporter 2 Inhibition. Diabetes Care 38:9, pages 1730-1735.
Crossref
Crossref
Jennifer D. Goldman-Levine. (2015) Combination Therapy When Metformin Is Not an Option for Type 2 Diabetes. Annals of Pharmacotherapy 49:6, pages 688-699.
Crossref
Crossref
Deborah Hinnen. (2015) Short commentary on empagliflozin and its potential clinical impact. Therapeutic Advances in Endocrinology and Metabolism 6:2, pages 68-81.
Crossref
Crossref
André J. Scheen. (2014) Pharmacodynamics, Efficacy and Safety of Sodium–Glucose Co-Transporter Type 2 (SGLT2) Inhibitors for the Treatment of Type 2 Diabetes Mellitus. Drugs 75:1, pages 33-59.
Crossref
Crossref
Korinne M. Piccolo & Joseph I. Boullata. 2015. Preventive Nutrition. Preventive Nutrition
83
113
.
L. H. Opie. (2014) Sodium Glucose Co-transporter 2 (SGLT2) Inhibitors: New among Antidiabetic Drugs. Cardiovascular Drugs and Therapy 28:4, pages 331-334.
Crossref
Crossref
Farhad M. Hasan, Mazen Alsahli & John E. Gerich. (2014) SGLT2 inhibitors in the treatment of type 2 diabetes. Diabetes Research and Clinical Practice 104:3, pages 297-322.
Crossref
Crossref
Chang Hee JungJung Eun JangJoong-Yeol Park. (2014) A Novel Therapeutic Agent for Type 2 Diabetes Mellitus: SGLT2 Inhibitor. Diabetes & Metabolism Journal 38:4, pages 261.
Crossref
Crossref
T. Ruiz Gracía & A.L. Calle Pascual. (2013) Estado actual del tratamiento farmacológico de la diabetes mellitus. Una aproximación práctica. Medicine - Programa de Formación Médica Continuada Acreditado 11:46, pages 2730-2740.
Crossref
Crossref
Ahasanul Hasan & Raquibul Hasan. (2021) Dapagliflozin Induces Vasodilation in Resistance-Size Mesenteric Arteries by Stimulating Smooth Muscle Cell K <sub>v</sub>7 Ion Channels. SSRN Electronic Journal.
Crossref
Crossref